| Amyloidosis |
1 |
1 |
| Heart |
0 |
0.65 |
| Heart Failure (HF) |
0 |
0.99 |
| Cardiovascular Imaging |
0 |
0.64 |
| Cardiomyopathy |
0 |
0.54 |
| Clinical Research |
0 |
0.52 |
| Cardiac MRI |
0 |
0.51 |
| Arrhythmia |
0 |
0.44 |
| Healthcare and Medical Technology |
0 |
0.39 |
| Cytokines |
0 |
0.26 |
| Ejection Fraction |
0 |
0.22 |
| Platelet Count |
0 |
0.22 |
| Patient Safety |
0 |
0.15 |
| Adherence |
0 |
0.13 |
| Adverse Effects |
0 |
0.13 |
| B-Type Natriuretic Peptide |
0 |
0.13 |
| Europe |
0 |
0.13 |
| Hospital |
0 |
0.13 |
| Immunology |
0 |
0.13 |
| New York |
0 |
0.13 |
| Prognosis |
0 |
0.13 |
| Troponin |
0 |
0.13 |
| Biologic Therapy |
0 |
0.1 |
| Deep Venous Thrombosis |
0 |
0.1 |
| Myocardial Infarction (MI) |
0 |
0.1 |
| Pulmonary Embolism |
0 |
0.1 |